Disease Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:8850
Name salivary gland cancer
Definition An oral cavity cancer that is located_in the salivary gland.
Source DiseaseOntology.org
Alt Ids DOID:9148 DOID:8873
Path disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer oral cavity cancer salivary gland cancer


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
BRAF V600E Vemurafenib salivary gland cancer predicted - sensitive detail...
HRAS mutant Tipifarnib salivary gland cancer predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01316757 Phase II Carboplatin + Cetuximab + Erlotinib + Paclitaxel Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer Completed USA 0
NCT01969578 Phase II Bicalutamide + Triptorelin Carboplatin + Paclitaxel Cisplatin + Doxorubicin Androgen Deprivation Therapy in Advanced Salivary Gland Cancer Unknown status ITA | FRA | DEU | BEL | AUT 3
NCT02091141 Phase II Erlotinib Alectinib Cobimetinib + Vemurafenib Pertuzumab + Trastuzumab Vismodegib Atezolizumab My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors Active, not recruiting USA 0
NCT02538510 Phase Ib/II Pembrolizumab + Vorinostat Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer and Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery Active, not recruiting USA 0
NCT02576431 Phase II Larotrectinib A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors (NAVIGATE) Recruiting USA | ITA | FRA | ESP | DEU | CAN | BEL 24
NCT02628067 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) Recruiting USA | ITA | FRA | ESP | DEU | CAN 14
NCT02636036 Phase I Enadenotucirev + Pembrolizumab Study of Enadenotucirev and Pembrolizumab in Subjects With Metastatic or Advanced Epithelial Tumors Completed USA 0
NCT02749903 Phase II Enzalutamide Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers Active, not recruiting USA 0
NCT02795156 Phase II Cabozantinib Afatinib Regorafenib Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations Completed USA 0
NCT03172624 Phase II Ipilimumab + Nivolumab Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer Active, not recruiting USA 0
NCT03319628 Phase I XMT-1536 First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b Recruiting USA | ITA | FRA | ESP | CAN | BEL | AUT 12
NCT03360890 Phase II Docetaxel + Pembrolizumab Synergy of Pembrolizumab Anti-PD-1 Immunotherapy With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors Recruiting USA 0
NCT03781986 Phase Ib/II APG-115 APG-115 in Salivary Gland Cancer Trial Recruiting USA 0
NCT03936959 Phase I LY3434172 A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer Completed USA | FRA | BEL 2
NCT04105543 Phase I CLR 131 CLR 131 Combined With Radiation for Head and Neck Cancer Active, not recruiting USA 0
NCT04209660 Phase II Lenvatinib + Pembrolizumab Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers Recruiting USA 0
NCT04246671 Phase Ib/II TAEK-VAC-HerBy TAEK-VAC-HerBy + unspecified ERBB2 antibody + unspecified immune checkpoint inhibitor Pertuzumab + TAEK-VAC-HerBy + Trastuzumab Ado-trastuzumab emtansine + TAEK-VAC-HerBy TAEK-VAC-HerBy + Trastuzumab Intravenous TAEK-VAC-HerBy Vaccine Alone and in Combination Treatment in HER2 Cancer Patients Recruiting USA 0
NCT04682431 Phase I Pembrolizumab + PY159 PY159 A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors Recruiting USA 0
NCT04704661 Phase I Ceralasertib + Trastuzumab deruxtecan Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial Recruiting USA 0
NCT04895735 Phase II Pembrolizumab + Pemetrexed Disodium Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer Recruiting USA 0
NCT05608876 Phase II Tigilanol tiglate A Clinical Study to Investigate the Efficacy of Tigilanol Tiglate Directly in Head and Neck Cancer Not yet recruiting 1